Asia
Tianjin Lisheng Pharmaceutical's Q1 2026 Profit Falls
Tianjin Lisheng Pharmaceutical (SHE:002393) booked 51.9 million yuan in attributable profit for the first quarter of 2026, falling from 55.3 million yuan in the prior-year period, according to a Friday Hong Kong bourse filing by parent Tianjin Development (HKG:0882).Shares of the company dropped nearly 6% in morning trade Friday.Earnings per share were 0.20 yuan, compared with 0.21 yuan a year earlier.Total operating income fell to 332.3 million yuan from 369.8 million yuan in the comparable, year-ago period.
HKG:0882SHE:002393
